Enterprise Therapeutics (TMEM16A Potentiator Portfolio) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) General Information
Description
Portfolio of TMEM16A potentiator program including ETD002. The portfolio is focused towards treating people with cystic fibrosis and has the potential to benefit people with other severe respiratory diseases characterized by excessive mucus congestion.
Contact Information
Corporate Office
- Brighton
- England, United Kingdom
Corporate Office
- Brighton
- England, United Kingdom
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) FAQs
-
Where is Enterprise Therapeutics (TMEM16A Potentiator Portfolio) headquartered?
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is headquartered in Brighton, United Kingdom.
-
What industry is Enterprise Therapeutics (TMEM16A Potentiator Portfolio) in?
Enterprise Therapeutics (TMEM16A Potentiator Portfolio)’s primary industry is Buildings and Property.
-
Is Enterprise Therapeutics (TMEM16A Potentiator Portfolio) a private or public company?
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is a Private company.
-
What is the current valuation of Enterprise Therapeutics (TMEM16A Potentiator Portfolio)?
The current valuation of Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is .
-
What is Enterprise Therapeutics (TMEM16A Potentiator Portfolio)’s current revenue?
The current revenue for Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is .
-
Who are Enterprise Therapeutics (TMEM16A Potentiator Portfolio)’s investors?
Enterprise Therapeutics, Epidarex Capital, Forbion, IP Group, and Novartis Venture Fund are 5 of 7 investors who have invested in Enterprise Therapeutics (TMEM16A Potentiator Portfolio).
-
When was Enterprise Therapeutics (TMEM16A Potentiator Portfolio) acquired?
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) was acquired on 07-Oct-2020.
-
Who acquired Enterprise Therapeutics (TMEM16A Potentiator Portfolio)?
Enterprise Therapeutics (TMEM16A Potentiator Portfolio) was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process